Understanding Cuvitru: Benefits, Side Effects, and Dosage Instructions
Cuvitru (immune globulin) is a medication derived from human plasma that is administered to patients with antibody deficiencies to help protect against infections. Plasma is a vital component of blood, providing its liquid base and containing various elements, such as water, blood clotting factors, plasma proteins, electrolytes, and immunoglobulins.
Cuvitru belongs to the immune globulins drug class and is FDA-approved for use as a monotherapy or adjunct therapy with other medications.
Cuvitru Therapy and Indications
Cuvitru is an immunoglobulin solution that is only administered by subcutaneous infusion. It works by replacing antibodies that are either not functioning correctly or not present in the human body, thereby helping to fight off infections. The FDA-approved doses aim to increase extremely low blood immunoglobulin levels to the required levels.
Cuvitru is recommended for several medical conditions, including:
- Primary Humoral Immunodeficiency (PI) in adults and children aged two years and above who have a congenital inability to produce antibodies.
- Patients with blood cancer experiencing low antibody production and recurrent infections when prophylactic antibiotics are not an option.
- Individuals with bone marrow cancer and those who have insufficient antibody production along with frequent infections.
- Patients who exhibit reduced antibody levels after receiving bone marrow cell transplants from a different person.
Patients receiving Cuvitru treatment may experience a range of side effects, including allergic reactions, symptoms that require prompt medical care, urinary issues, elevated or decreased blood pressure, respiratory infections and inflammation, aseptic meningitis, and injection site reactions. Listed below are some of the possible side effects from using Cuvitru:
- Skin rash
- Elevated temperature
- Difficulty breathing
- Chest constriction
- Breathing issues
- Shortness of breath
- Swollen, red skin
- Facial and lip swelling
Symptoms That Require Prompt Medical Care:
- High fever
- Abdominal distension
- Abdominal discomfort
- Discolored urine
- Throat pain
- Mood Swings
- Excessive sweating
- Irregular heartbeat
- Visual disturbances
- Speech issues
- Weight gain
- Increased urination
- Trouble urinating
Blood Pressure Changes:
- Impaired vision
Respiratory Infections and Inflammation:
- Nasal inflammation
- Sinus infection
- Bronchial asthma
Aseptic Meningitis (May Need Immediate Medical Attention):
- High fever
- Cold sensations
- Neck stiffness
- Stomach upset
- Sensitivity to light
Injection Site Reactions:
- Local itchiness
- Slight discomfort
- Skin redness
Note: Cuvitru injection site reactions typically resolve within hours and usually do not necessitate medical intervention. Such reactions become less frequent as the body gets used to the medication.
Risk Factors for Blood Clots
Cuvitru has a Black Box Warning because of the possibility of blood clots. Patients with certain risk factors, such as estrogen use, advanced age, a sedentary lifestyle, hypercoagulable conditions, or a history of previous blood clots, are at an increased risk.
In order to minimize or mitigate the risk of blood clots, the manufacturer advises administering the infusion at the lowest possible dose and infusion rate. It is essential to monitor for any signs and symptoms throughout the treatment process.
Cuvitru is delivered beneath the skin (subcutaneously) and is usually administered by a qualified healthcare practitioner.
Dosing varies from patient to patient, taking into account factors such as body weight, medical history, blood IgG levels, current conditions, and clinical response to the treatment.
Considering these factors, the patient (either a child or an adult) may be prescribed an initial loading dose ranging from 1.0 to 2.5 ml/kg of body weight, divided over several consecutive days .
After this initial loading dose, patients will begin to receive Cuvitru infusions at consistent intervals, which can range from daily to once every two weeks.
Following the loading dose, the total monthly dose typically varies between 1.5 and 5.0 ml/kg of body weight. To attain the desired clinical outcome and serum IgG levels, the physician may modify the dose over time.
For those transitioning from a different IVIG brand, the Cuvitru dosage will be determined by the previous IVIG dosage and adjusted based on the quantity and frequency of infusions.
Do not alter the dosage or the dosing interval without consulting the doctor.
In case of a missed dose, contact the doctor promptly to obtain an updated dosing schedule. Refrain from doubling the dose to compensate.
Cuvitru is used to treat various conditions, including primary immunodeficiency diseases (PI), idiopathic thrombocytopenic purpura (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), chronic immune thrombocytopenic purpura, and secondary humoral immunodeficiency diseases.
Cuvitru is also used to boost muscle strength in patients with multifocal motor neuropathy (MMN).
Cuvitru Cost and Copay Assistance
The cost of Cuvitru can depend on several factors, including:
⦁ The pharmacy providing the medication
⦁ The prescribed dose
⦁ The patient’s insurance coverage
Cuvitru is provided in single-dose glass vials with typical volumes of 5 ml, 10 ml, 20 ml, 40 ml, and 50 ml protein per vial.
The base price shown on various pharmacy websites is determined by the manufacturer, Takeda Pharmaceutical, and does not include shipping fees or local taxes.
The cost of Cuvitru at different pharmacies is approximately $210 (around $42 per unit) for a 5 ml supply. Consequently, the total cost for a 50 ml supply is roughly $2,100 .
Pharmaceutical firms often establish various patient assistance programs (PAPs) to provide free or reduced-price medications to individuals who cannot afford their prescriptions.
One such initiative is Takeda’s OnePath Co-Pay Assistance Program, which supports patients prescribed Cuvitru  . To be eligible for this program, patients must have commercial insurance.
This program helps with certain out-of-pocket treatment expenses and aids in navigating the health insurance process. It also offers in-house training from qualified personnel and access to educational and support services.
Additionally, the HelloCUVITRU program is a complimentary trial that covers the complete cost of the initial four Cuvitru infusions, as well as the necessary administration supplies . To qualify for this program, patients must be at least 2 years old, have not previously participated in the program, and are not currently using the medication.
Cuvitru is a crucial medication for patients with immunodeficiency conditions and helps protect against infections by replacing antibodies in the body. It is essential for patients to consult with their healthcare professional to determine the appropriate dosing regimen and to monitor for potential side effects. As the cost of Cuvitru can be high, it is recommended to explore available assistance programs to help cover treatment costs. By following the prescribed treatment plan and maintaining open communication with healthcare providers, patients can effectively manage their immunodeficiency conditions and improve their overall quality of life.
This information is not a substitute for medical advice or treatment. Talk to your doctor or healthcare provider about your medical condition prior to starting any new treatment. AmeriPharma Infusion Center assumes no liability whatsoever for the information provided or for any diagnosis or treatment made as a result, nor is it responsible for the reliability of the content.
AmeriPharma Infusion Center does not operate all the websites/organizations listed here, nor is it responsible for the availability or reliability of their content. These listings do not imply or constitute an endorsement, sponsorship, or recommendation by AmeriPharma Infusion Center.
This webpage may contain references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with AmeriPharma Infusion Center.